No Data
Some Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) Shareholders Look For Exit As Shares Take 26% Pounding
Jiangxi Fushine Pharmaceutical (300497.SZ) plans to establish two joint venture companies to promote the development of the synthetic biology sector.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that the company will hold the second meeting of the fourth board of directors on December 1, 2024...
Would Jiangxi Fushine Pharmaceutical (SZSE:300497) Be Better Off With Less Debt?
Shareholder Yu Wenjun of jiangxi fushine pharmaceutical (300497.SZ) plans to reduce his shareholding by no more than 0.82%.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that it holds 17.6218 million shares of the company (excluding buyback...
Jiangxi Fushine Pharmaceutical (300497.SZ): Currently, the company has achieved an annual production capacity of 1200 tons of microbial protein.
On November 14, Gelonghui reported that Jiangxi Fushine Pharmaceutical (300497.SZ) stated on the investor interaction platform that the company plans to establish sales companies for microbial protein in Shanghai and Singapore, intensifying efforts to promote the sales of microbial protein in various sectors of the consumer market. Currently, the company's microbial protein has achieved an annual capacity of 1,200 tons and is constructing a microbial protein production line with a capacity of 0.02 million tons per year. While consolidating technology and production, the company is starting to increase efforts to promote microbial protein in various consumer product marketing strategies. Downstream application scenarios include: health food, functional beverages, dining, special medical food, pet food, and more.
Fushine Pharmaceutical to Set Up Domestic, International Subsidiaries
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues Yet
